{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:21:25Z","timestamp":1764134485638,"version":"3.46.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Peripheral T-cell lymphoma non-specific type (PTCL-NOS) is the most common subtype of mature T-cell tumors, which is clinically characterized by high invasiveness and poor prognosis. It is worth noting that PTCL-NOS rarely abnormally expresses B-cell antigens (such as CD20). This rare immunophenotype makes it easily confused with B-cell non-Hodgkin\u2019s lymphoma (B-NHL), which brings challenges to clinical diagnosis and may lead to wrong treatment decisions. At present, CHOP regimen, as the first-line standard therapy for PTCL-NOS, has the limitations of low complete remission rate and high recurrence risk. In order to improve the efficacy, recent studies have confirmed that the combination of etoposide (CHOPE regimen) on the basis of CHOP regimen can significantly improve the treatment response for newly diagnosed patients aged \u2264 65 years. This paper reports a rare case of PTCL-NOS with abnormal expression of CD20 in the tongue. The patient received four cycles of CHOPE regimen after surgical resection of the primary tumor and underwent PET\/CT mid-term evaluation. Through this case, we aim to further explore the pathological diagnosis difficulties of such rare cases and preliminarily evaluate the clinical application value of CHOPE regimen.<\/jats:p>","DOI":"10.3389\/fmed.2025.1669823","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:16:15Z","timestamp":1764134175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Chenyu","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehong","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes.","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/978-1-4419-0296-2_15","article-title":"Normal and pathological V(D)J recombination: contribution to the understanding of human lymphoid malignancies.","volume":"650","author":"Dadi","year":"2009","journal-title":"Adv Exp Med Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3969\/jissn.1007-8096.2017.10.007","article-title":"Clinicopathologic features of CD20-positive T cell lymphoma: two cases report.","volume":"24","author":"Xiao","year":"2017","journal-title":"Chinese J Diagnostic Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/PAS.0b013e31817d7452","article-title":"CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature.","volume":"32","author":"Rahemtullah","year":"2008","journal-title":"Am J Surg Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1553969","DOI":"10.3389\/fonc.2025.1553969","article-title":"CD20-positive peripheral T-cell lymphoma not otherwise specified: a case series and review of the literature.","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/cyto.b.21852","article-title":"CD20-positive primary nasal peripheral T-cell lymphoma: an analysis of one case and review of the literature.","volume":"98","author":"Li","year":"2019","journal-title":"Cytometry B Clin Cytom."},{"key":"B7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12185-015-1841-x","article-title":"CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review.","volume":"102","author":"Kakinoki","year":"2015","journal-title":"Int J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.13315\/j.cnki.cjcep.2013.09.008","article-title":"Clinical pathological feature and molecular genetic analysis of CD20 positive peripheral T cell lymphoma and review literature.","volume":"29","author":"Xin-xia","year":"2013","journal-title":"Chinese J Clin Exp Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/diagnostics10060341","article-title":"Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and CD79a: a case report and review of the literature.","volume":"10","author":"Mangogna","year":"2020","journal-title":"Diagnostics."},{"key":"B10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/diagnostics10090629","article-title":"Clinical remission in a 72-year-old patient with a massive primary cutaneous peripheral T-cell lymphoma-NOS of the eyelid, following combination chemotherapy with etoposide plus COP.","volume":"10","author":"Iluta","year":"2020","journal-title":"Diagnostics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3760\/cma.jcn112151-20220121-00051","article-title":"Gastric peripheral T-cell lymphoma-not otherwise specified with CD20 and CD79\u03b1 aberrant expression: report of a case.","volume":"51","author":"Shuangshuang","year":"2022","journal-title":"Zhonghua Bing Li Xue Za Zhi."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1111\/j.1365-4632.2012.05483.x","article-title":"A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy.","volume":"53","author":"Kamata","year":"2014","journal-title":"Int J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/path.1711520202","article-title":"Cell lymphomas in adults : clinicopathological study of eighteen cases.","volume":"152","author":"Ramsay","year":"1987","journal-title":"J Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/modpathol.3880229","article-title":"CD20-positive peripheral T-cell lymphoma: report of a case after nodular sclerosis Hodgkin\u2019s disease and review of the literature.","volume":"13","author":"Mohrmann","year":"2000","journal-title":"Modern Pathol."},{"key":"B15","first-page":"263","article-title":"CD20 Positive T-cell Lymphoma\/Leukemia: a rare entity with potential diagnostic pitfalls.","volume":"37","author":"Buckner","year":"2007","journal-title":"Ann Clin Lab Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1309\/hpygflnxkfbhdqev","article-title":"Primary CD20+CD10+CD8+ T-Cell lymphoma of the skin with dual IgH and TCR? rearrangement.","volume":"126","author":"Magro","year":"2006","journal-title":"Am J Clin Pathol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/modpathol.3880133","article-title":"Immunoreactivity of B-Cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK\/T-) cell lymphomas.","volume":"13","author":"Blakolmer","year":"2000","journal-title":"Mod Pathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0199","DOI":"10.1097\/MD.0000000000010199","article-title":"T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX).","volume":"97","author":"Shao","year":"2018","journal-title":"Medicine."},{"key":"B19","doi-asserted-by":"publisher","first-page":"183134","DOI":"10.1155\/2013\/183134","article-title":"Peripheral T-cell lymphoma with aberrant expression of CD19, CD20, and CD79a: case report and literature review.","volume":"2013","author":"Matnani","year":"2013","journal-title":"Case Rep Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.leukres.2008.09.034","article-title":"Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.","volume":"33","author":"Hirata","year":"2009","journal-title":"Leuk Res."},{"key":"B21","first-page":"413","article-title":"Extranodal CD20-positive peripheral T-cell lymphoma presenting with ad renal and testicular masses.","volume":"50","author":"Makita","year":"2009","journal-title":"Rinsho Ketsueki."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.11406\/rinketsu.58.2227","article-title":"Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine.","volume":"58","author":"Teshima","year":"2017","journal-title":"Rinsho Ketsueki."},{"key":"B23","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.4049\/jimmunol.142.7.2560","article-title":"Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).","volume":"142","author":"Tedder","year":"1989","journal-title":"J Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.critrevonc.2010.07.007","article-title":"Peripheral T-cell lymphoma \u2013 Not otherwise specified.","volume":"79","author":"Savage","year":"2011","journal-title":"Crit Rev Oncol Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/10428194.2015.1083097","article-title":"Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.","volume":"57","author":"Toya","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.","volume":"5","author":"Klein","year":"2014","journal-title":"mAbs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience.","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2023021789","article-title":"Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0305-7372(79)80045-6","article-title":"Etoposide (VP-16-213).","volume":"6","author":"Issell","year":"1979","journal-title":"Cancer Treat Rev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:16:18Z","timestamp":1764134178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":29,"alternative-id":["10.3389\/fmed.2025.1669823"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1669823","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1669823"}}